CAPITAL SOLEIL 15
LOE Approachingavobenzone; ecamsule; octocrylene
NDATOPICALCREAM
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CAPITAL SOLEIL 15 (avobenzone; ecamsule; octocrylene). Approved for sunburns, wind burned, chapped lips. First approved in 2006.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPITAL SOLEIL 15 is a topical sunscreen cream containing avobenzone, ecamsule, and octocrylene that provides broad-spectrum UV protection. It is indicated for prevention and treatment of sunburns, wind-burned skin, and chapped lips. The active ingredients work as UV absorbers to shield skin from UVA and UVB radiation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting consolidation and defensive strategies within the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.